NICE Recommends ODM in Trauma Patients with Major Haemorrhaging

The UK’s National Institute for Health and Care Excellence (NICE) publishes guidance on many aspects of patient care. These documents are often collated into treatment pathways, bringing together everything NICE has to say on a topic in a single flowchart. These flowcharts are regularly updated as new NICE guidance is published.

One pathway, newly updated on January 9th 2019, is the hospital treatment of major haemorrhaging in trauma patients, which can be found here.

And once more NICE makes the clear recommendation to utilise oesophageal Doppler monitoring (ODM), re-emphasising its previous Medical Technology Guidance (MTG3). As the guidance states, the case for its adoption is “supported by the evidence.”

“The CardioQ-ODM should be considered for use in patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring.”

Yet again then, it seems that those who have most closely, and independently evaluated ODM technology find strong supporting evidence that warrants its inclusion in official guidance.

For Deltex, CEO Andy Mears states, “it’s perhaps unsurprising to see NICE recommending a technology that gives clinicians the most accurate, real-time haemodynamic data. Nonetheless it is very rewarding for the committed people of Deltex Medical to see our system gaining recognition for use in such life-changing clinical circumstances.”


Terminus Road | Chichester | PO19 8TX | United Kingdom

  • Enquiries: +44 1243 774837
  • Email:
  • Deltex App:


Registered in England & Wales Company No: 1691369